Back to News
Market Impact: 0.15
Yamo Pharmaceuticals Announces Autism Trial Registry Following Global Surge in Family Interest
Source: PR Newswire
Healthcare & Biotech
Yamo Pharmaceuticals says it has received more than 6,000 inquiries since May about L1-79, its investigational drug for core autism spectrum disorder symptoms. The company opened a registration site intended to help speed enrollment in a Phase 3 trial; the article provides no trial results or enrollment figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- HIMS jumps 7% on peptide tailwind — but Citi sees 17% downside from here
- Alignment Healthcare Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Alignment Healthcare (ALHC)